scispace - formally typeset
S

Steven M. Dubinett

Researcher at University of California, Los Angeles

Publications -  339
Citations -  17983

Steven M. Dubinett is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 68, co-authored 312 publications receiving 16127 citations. Previous affiliations of Steven M. Dubinett include United States Department of Veterans Affairs & West Los Angeles College.

Papers
More filters
Journal ArticleDOI

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.

TL;DR: A new pathway of prostaglandin-induced immune dysfunction is demonstrated and a novel mechanism that can help explain the cancer prevention effects of COX-2 inhibitors is provided, which represents a clinical approach to enhance the therapeutic potential of cancer immunotherapies.
Journal ArticleDOI

Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells

TL;DR: PGE2 enhances the in vitro inhibitory function of human purified CD4+CD25+ T reg cells and induces a regulatory phenotype in CD4-CD25− T cells, the first report indicating that PGE2 can modulate FOXP3 expression and T reg function in human lymphocytes.
Journal Article

Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.

TL;DR: The results indicate that lung tumor-derived PGE2 plays a pivotal role in promoting lymphocyte and macrophage IL-10 induction while simultaneously inhibiting macrophages IL-12 production.
Journal ArticleDOI

Tumor Cyclooxygenase-2/Prostaglandin E2–Dependent Promotion of FOXP3 Expression and CD4+CD25+ T Regulatory Cell Activities in Lung Cancer

TL;DR: In vivo inhibition of COX-2/PGE2 suppresses Treg cell activity and enhances antitumor responses, and transfer of Treg cells or administration of PGE2 to mice receiving COx-2 inhibitors reversed these effects.